

# NOW ENROLLING IN MELANOMA




PHASE 3 (NCT03635983)

## PIVOT IO 001: Bempegaldesleukin with nivolumab in patients with unresectable or metastatic melanoma

A randomized, open-label study of bempegaldesleukin (BEMPEG; NKTR-214) plus nivolumab (NIVO) versus NIVO monotherapy in patients with previously untreated, unresectable or metastatic melanoma<sup>1,2</sup>

**ENROLL NOW**

Scan here to find out more about this clinical study at [ClinicalTrials.gov](https://ClinicalTrials.gov)



Bempegaldesleukin is an investigational first-in-class CD122-preferential IL-2–pathway agonist<sup>3</sup>

Nivolumab is a PD-1 blocking antibody<sup>4</sup>

<sup>a</sup>Randomization is stratified by PD-L1 status, *BRAF* status and AJCC stage (8<sup>th</sup> edition).

AJCC, American Joint Committee on Cancer; BEMPEG, bempegaldesleukin (NKTR-214); CBR, clinical benefit rate; DOCR, duration of overall complete response; DOR, duration of response; IL-2, interleukin-2; NIVO, nivolumab; ORR, objective response rate; OS, overall survival; PD-1, programmed death-1; PD-L1, programmed death-ligand 1; PFS, progression-free survival; R, randomized; TTR, time to treatment response.

1. [ClinicalTrials.gov. NCT03635983](https://clinicaltrials.gov/ct2/show/NCT03635983). <https://clinicaltrials.gov/ct2/show/NCT03635983>. Accessed May 1, 2020. 2. Khushalani NI, *et al*. Presented at: ASCO; May 31–June 4, 2019; Chicago, IL. 3. Charych DH, *et al*. *Clin Cancer Res* 2016;22:680–690. 4. Opdivo (nivolumab) Prescribing Information (Princeton, NJ: Bristol Myers Squibb; revised: May 2020).

# CLINICAL TRIALS WITH BEMPEGALDESLEUKIN AND NIVOLUMAB ARE NOW ENROLLING


NEKTAR

 Bristol Myers Squibb™

Bempegaldesleukin (BEMPEG; NKTR-214) in combination with nivolumab (NIVO) leverage two immuno-oncology pathways with the aim of addressing the unmet needs of patients living with cancer

**FIND OUT MORE**

Scan here to discover more about BEMPEG at Nektar.com



BEMPEG, bempegaldesleukin (NKTR-214); NIVO, nivolumab.

**FOR EDUCATIONAL PURPOSES ONLY.**

This compound and the combination of agents and their uses have not been approved.

Nektar Therapeutics, 455 Mission Bay Boulevard, South San Francisco, California 94158. Copyright Nektar Therapeutics © 2020. All rights reserved.